ADARx Pharmaceuticals, Inc. (ADRX)

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing small interfering RNA, or siRNA, medicines. These drugs are designed to silence specific genes that drive disease, acting at the RNA level without altering a patient's DNA.

The company aims to extend siRNA therapy beyond the liver, where such drugs have traditionally been focused, to address a broader range of diseases with significant unmet medical need. Its pipeline includes several clinical-stage programs, with its most advanced candidate in late-stage development, along with additional preclinical programs.

ADARx was founded in 2019 and is headquartered in San Diego, California. It completed its initial public offering on Nasdaq in September 2026.